2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …
Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure
H Tsutsui, T Ide, H Ito, Y Kihara, K Kinugawa… - Circulation …, 2021 - jstage.jst.go.jp
After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …
were approved and important evidence for pharmacologic therapy and nonpharmacologic …
[HTML][HTML] Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled …
C Baigent, JR Emberson, R Haynes, WG Herrington… - The Lancet, 2022 - thelancet.com
Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …
[HTML][HTML] The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
JA Spertus, MC Birmingham, M Nassif, CV Damaraju… - Nature medicine, 2022 - nature.com
Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …
DC Wheeler, BV Stefánsson, N Jongs… - The lancet Diabetes & …, 2021 - thelancet.com
Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …
Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction
CG Santos-Gallego, AP Vargas-Delgado… - Journal of the American …, 2021 - jacc.org
Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial
Background: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …
heart failure with reduced ejection fraction, but additional information is needed about …
Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF
Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …
chronic kidney disease that complicates pharmacological management and is associated …
Heart failure with reduced ejection fraction: a review
Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …